EUVIMEDEUVIMED entdecken
Metaanalyse

PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis

M S Beshr, I A Beshr, M Al Hayek, S M Alfaqaih, M Abuajamieh, E Basheer, A K Wali, M Ekreer, I Chenfouh, A Khashan, E T Hassan, S M Elnaami und 1 weitere

Clinical Oncology · 2024

DOI: 10.1016/j.clon.2024.09.007 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Oncology, 2024. Verfasst von M S Beshr und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sana'a University, Faculty of Medicine and Health Sciences, Sana'a, Yemen. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Stomach Neoplasms, Adenocarcinoma, Esophagogastric Junction. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Advanced gastroesophageal cancers are still associated with poor outcomes. We aim to study PD-1/PD-L1 inhibitors in phase III clinical trials that have compared them to chemotherapy in gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma. MATERIALS AND METHODS: On March 28, 2024, we searched: PubMed, Embase, Cochrane Library, Web of Science, Scopus, and ClinicalTrials.gov. We only included randomized clinical trials for PD-1/PD-L1 inhibitors alone or with chemo vs chemotherapy in advanced gastric, GEJ, or esophageal adenocarcinoma. The primary endpoints were overall survival and progression-free survival. A subgroup analysis was conducted for the following variables: treatment line, type of intervention, age group, gender, ECOG Performance Status, combined positive scores (CPS), microsatellite instability (MSI) status, liver metastasis, and primary tumor location. RESULTS: Only 10 out of 8,942 articles were included, involving 6,782 patients. PD-1/PD-L1 inhibitors showed a significant improvement in the overall survival compared to chemotherapy alone (hazard ratio (HR): 0.86, 95% CI: 0.80-0.93; p = 0.0002). Combining PD-1/PD-L1 inhibitors with chemotherapy significantly improved overall and progression-free survival compared to monotherapy (combined therapy HR 0.80; p < 0.00001 vs. monotherapy HR 0.98; p = 0.77). CPS ≥1 had an HR of 0.78 (95% CI: 0.73-0.84; p < 0.00001), CPS ≥10 had an HR of 0.67 (95% CI: 0.59-0.76; p < 0.00001), and MSI-high status had an HR of 0.35 (95% CI: 0.24-0.52; p < 0.00001). Esophageal adenocarcinoma, reported in three trials, did not show significant improvement in the overall survival (HR 0.89; 95% CI: 0.69-1.14; p = 0.37). CONCLUSION: PD-1/PD-L1 inhibitors have significantly improved overall survival, and combining them with chemotherapy is more effective than monotherapy. Both CPS ≥10 and MSI-H showed an added benefit to overall survival and should be included in biomarker investigations. Clinical trials are needed for second-line treatments and esophageal adenocarcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsStomach NeoplasmsAdenocarcinomaEsophagogastric JunctionImmune Checkpoint InhibitorsHumansAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenErb-b2 Receptor Tyrosine KinasesProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

Advanced gastroesophageal cancerEsophageal adenocarcinomaGastric adenocarcinomaGastroesophageal adenocarcinomaImmune check pointsPD-1 inhibitor, PD-1/PD-L1 inhibitors

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenErb-b2 Receptor Tyrosine KinasesProgrammed Cell Death 1 ReceptorCD274 protein, humanERBB2 protein, human

Autor:innen und Institutionen

  • Sana'a University, Faculty of Medicine and Health Sciences, Sana'a, Yemen.
  • Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic.
  • Faculty of Medicine, University of Misurata, Misurata, Libya.
  • Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Faculty of Medicine, Sebha University, Sabha, Libya.
  • Faculty of Medicine, University of Tripoli, Libya.

Zitieren

APA

Beshr, M. S., Beshr, I. A., Al Hayek, M., Alfaqaih, S. M., Abuajamieh, M., Basheer, E., Wali, A. K., Ekreer, M., Chenfouh, I., Khashan, A., Hassan, E. T., Elnaami, S. M., & Elhadi, M. (2024). PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis. Clinical Oncology. https://doi.org/10.1016/j.clon.2024.09.007

Vancouver

Beshr MS, Beshr IA, Al Hayek M, Alfaqaih SM, Abuajamieh M, Basheer E, et al. PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis. Clinical Oncology. 2024. doi:10.1016/j.clon.2024.09.007

BibTeX
@article{Beshr2024,
  author = {Beshr, M S and Beshr, I A and Al Hayek, M and Alfaqaih, S M and Abuajamieh, M and Basheer, E and Wali, A K and Ekreer, M and Chenfouh, I and Khashan, A and Hassan, E T and Elnaami, S M and Elhadi, M},
  title = {PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis},
  journal = {Clinical Oncology},
  year = {2024},
  doi = {10.1016/j.clon.2024.09.007}
}
Kostenlos starten →